{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adoptive+Cellular+Immunotherapy", "query": { "condition": "Adoptive Cellular Immunotherapy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 185, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adoptive+Cellular+Immunotherapy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T09:27:17.945Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00566098", "title": "Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "MILs", "type": "BIOLOGICAL" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "PCV13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2007-11", "completion_date": "2018-10", "has_results": true, "last_update_posted_date": "2023-05-26", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00566098" }, { "nct_id": "NCT00924001", "title": "Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Malignant Melanoma", "Melanoma, Experimental" ], "interventions": [ { "name": "DMF5 Melanoma Reactive TIL", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2007-08", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2012-10-25", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00924001" }, { "nct_id": "NCT03412877", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Breast Cancer", "Gastrointestinal/Genitourinary Cancers", "Neuroendocrine Tumors", "Multiple Myeloma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (KEYTRUDA(R))", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 285, "start_date": "2018-09-06", "completion_date": "2028-03-23", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412877" }, { "nct_id": "NCT00248430", "title": "Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "therapeutic allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "melphalan", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 20, "start_date": "2003-08", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2010-09-21", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248430" }, { "nct_id": "NCT02188719", "title": "Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Liver Transplantation" ], "interventions": [ { "name": "Anti-Thymocyte Globulin - Rabbit", "type": "BIOLOGICAL" }, { "name": "darTreg Infusion", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Anti-Infective Prophylaxis", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Blood draws", "type": "PROCEDURE" }, { "name": "Liver biopsies", "type": "PROCEDURE" }, { "name": "Liver transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 15, "start_date": "2014-12-17", "completion_date": "2019-06-18", "has_results": true, "last_update_posted_date": "2020-09-22", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 3, "location_summary": "San Francisco, California • Chicago, Illinois • Rochester, Minnesota", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02188719" }, { "nct_id": "NCT01445132", "title": "Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Allogeneic Cell Therapy w/ Tumor-derived Lypho", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 11, "start_date": "2007-01-11", "completion_date": "2013-04-24", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445132" }, { "nct_id": "NCT01106235", "title": "Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stage IV Melanoma" ], "interventions": [ { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 12, "start_date": "2010-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-12-21", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01106235" }, { "nct_id": "NCT04837547", "title": "PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 24, "start_date": "2021-09-20", "completion_date": "2032-09", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 3, "location_summary": "Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04837547" }, { "nct_id": "NCT02621021", "title": "A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "young TIL", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 53, "start_date": "2015-12-04", "completion_date": "2029-06-16", "has_results": false, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02621021" }, { "nct_id": "NCT03269526", "title": "BATs Treatment for Pancreatic Cancer, Phase Ib/II", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Pancreatic Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "EGFR BATs after standard of care chemo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2017-07-28", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-06-10T09:27:17.945Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03269526" } ] }